ORZORA: OPEN-LABEL PHASE IV TRIAL OF OLAPARIB IN PATIENTS WITH BRCA-MUTATED OVARIAN CANCER

被引：0
|
作者：
Pignata, S. [1 ]
Lewis, J. [2 ]
Tchakov, I. [2 ]
Robertson, J. D. [3 ]
Morris, T. [3 ]
Jayawardene, D. [4 ]
Tyczynski, J. E. [4 ]
Hodgson, D. R. [3 ]
Mills, J. [3 ]
Di Maio, M. [5 ]
机构：
[1] Natl Canc Inst Naples, Urogynecol Dept, Naples, Italy
[2] AstraZeneca, Global Med Affairs, Cambridge, England
[3] AstraZeneca, Global Clin Dev, Macclesfield, Cheshire, England
[4] AstraZeneca, Global Medicines Dev, Gaithersburg, MD USA
[5] Univ Turin, Dept Oncol, Turin, Italy
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-0933
引用
收藏
页码：1469 / 1470
页数：2
相关论文
共 50 条
  • [1] Olaparib for BRCA-mutated advanced ovarian cancer
    de Lartigue, Jane
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 206 - 208
  • [2] OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer
    Nicum, S.
    Strauss, V. Y.
    McGregor, N.
    McNeish, I.
    Roux, R.
    Hall, M.
    Michael, A.
    Roberts, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
    Munroe, Marklie
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
  • [4] Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
    Domchek, Susan M.
    Postel-Vinay, Sophie
    Im, Seock-Ah
    Park, Yeon Hee
    Delord, Jean-Pierre
    Italiano, Antoine
    Alexandre, Jerome
    You, Benoit
    Bastian, Sara
    Krebs, Matthew G.
    Wang, Ding
    Waqar, Saiama N.
    Lanasa, Mark
    Rhee, Joon
    Gao, Haiyan
    Rocher-Ros, Vidalba
    Jones, Emma, V
    Gulati, Sakshi
    Coenen-Stass, Anna
    Kozarewa, Iwanka
    Lai, Zhongwu
    Angell, Helen K.
    Opincar, Laura
    Herbolsheimer, Pia
    Kaufman, Bella
    LANCET ONCOLOGY, 2020, 21 (09): : 1155 - 1164
  • [5] Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
    Fanucci, Kristina A.
    Pilat, Mary Jo
    Shyr, Derek
    Shyr, Yu
    Boerner, Scott A.
    Durecki, Diane
    Noonan, Anne
    Abramson, Vandana
    Santa-Maria, Cesar
    Han, Hyo
    Nanda, Rita
    Dees, Elizabeth Claire
    Park, Haeseong
    Buys, Saundra
    Peswani, Namrata
    Chew, Helen
    Assad, Hadeel
    Wulf, Gerburg
    Richardson, Angelique
    Trivedi, Meghna S.
    Brufsky, Adam
    Abbruzzese, James
    Afghahi, Anosheh
    Sharon, Elad
    Schalper, Kurt
    LoRusso, Patricia
    CANCER RESEARCH, 2023, 83 (08)
  • [6] The efficacy of olaparib in BRCA-mutated ovarian cancer: a systematic review
    Wibisono, M. G.
    Wibisono, M. H.
    Sabran, M. Z.
    Wibisono, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1403 - S1404
  • [7] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
    Saleh, Naveed
    Copur, Mehmet Sitki
    ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
  • [8] An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
    Domchek, S. M.
    Postel-Vinay, S.
    Im, S-A
    Park, Y. Hee
    Delord, J-P
    Italiano, A.
    Alexandre, J.
    You, B.
    Bastian, S.
    Krebs, M. G.
    Waqar, S.
    Lanasa, M.
    Angell, H. K.
    Tang, M.
    Gresty, C.
    Opincar, L.
    Herbolsheimer, P.
    Kaufman, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Adjuvant Olaparib in BRCA-Mutated Breast Cancer
    Nozawa, Kazuki
    Yoshimura, Akiyo
    Iwata, Hiroji
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1439 - 1439
  • [10] Adjuvant Olaparib in BRCA-Mutated Breast Cancer REPLY
    Tutt, Andrew N. J.
    Garber, Judy E.
    Geyer, Charles E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1440 - 1440
12345